Mizuho began coverage on shares of Humana (NYSE:HUM) in a report published on Thursday, 24/7 WallStreet reports. The brokerage issued a buy rating and a $316.00 target price on the insurance provider’s stock.

HUM has been the topic of a number of other research reports. UBS Group boosted their target price on Humana from $266.00 to $317.00 and gave the company a neutral rating in a research note on Thursday, August 1st. SunTrust Banks boosted their target price on Humana to $340.00 and gave the company a hold rating in a research note on Thursday, August 1st. Cantor Fitzgerald upgraded Humana from a neutral rating to an overweight rating and boosted their target price for the company from $300.00 to $345.00 in a research note on Monday, August 12th. Deutsche Bank initiated coverage on Humana in a research note on Thursday, September 12th. They issued a hold rating and a $300.00 target price on the stock. Finally, ValuEngine upgraded Humana from a sell rating to a hold rating in a research note on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $333.30.

NYSE:HUM traded up $3.76 during trading hours on Thursday, hitting $289.26. 1,863,980 shares of the company’s stock traded hands, compared to its average volume of 1,137,260. The firm has a market cap of $38.57 billion, a P/E ratio of 19.88, a P/E/G ratio of 1.23 and a beta of 0.83. Humana has a twelve month low of $225.65 and a twelve month high of $355.88. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. The stock’s fifty day moving average price is $270.24 and its two-hundred day moving average price is $267.19.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share for the quarter, beating the consensus estimate of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm had revenue of $16.25 billion for the quarter, compared to analyst estimates of $15.88 billion. During the same period in the previous year, the firm earned $3.96 earnings per share. Humana’s quarterly revenue was up 13.9% on a year-over-year basis. On average, equities research analysts predict that Humana will post 17.67 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, September 27th. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. Humana’s dividend payout ratio (DPR) is presently 15.12%.

In other news, insider Brian P. Leclaire sold 7,239 shares of the company’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the sale, the insider now owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.54% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Maverick Capital Ltd. boosted its stake in Humana by 150.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock valued at $411,408,000 after purchasing an additional 932,778 shares during the period. Wells Fargo & Company MN boosted its stake in Humana by 1.8% during the 2nd quarter. Wells Fargo & Company MN now owns 1,367,476 shares of the insurance provider’s stock valued at $362,790,000 after purchasing an additional 24,314 shares during the period. Bank of New York Mellon Corp boosted its stake in Humana by 1.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,181,373 shares of the insurance provider’s stock valued at $313,417,000 after purchasing an additional 21,207 shares during the period. Amundi Pioneer Asset Management Inc. boosted its stake in Humana by 76.7% during the 2nd quarter. Amundi Pioneer Asset Management Inc. now owns 877,582 shares of the insurance provider’s stock valued at $232,822,000 after purchasing an additional 380,979 shares during the period. Finally, California Public Employees Retirement System boosted its stake in Humana by 5.5% during the 2nd quarter. California Public Employees Retirement System now owns 783,082 shares of the insurance provider’s stock valued at $207,752,000 after purchasing an additional 40,631 shares during the period. Institutional investors own 92.77% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: What is an Initial Public Offering (IPO)?

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.